![Bent K. Jakobsen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bent K. Jakobsen
Directeur Général chez
Accession Therapeutics Limited
Fortune : 251 688 $ au 30/06/2026
Profil
Bent K.
Jakobsen is the founder of Avidex Ltd. (1999), Adaptimmune Therapeutics Plc (2008), Adaptimmune Ltd. (2008), Immunocore Holdings Plc (2008), and Accession Therapeutics Ltd. (2021).
Titles held at these companies included Executive Director-Research at Avidex Ltd., Chief Scientific Officer at Adaptimmune Ltd., Director & Chief Scientific Officer at Immunocore Holdings Plc, and Chief Executive Officer & Director at Accession Therapeutics Ltd. Current jobs include Chairman at Engimmune Therapeutics AG since 2022, Non-Executive Director at Zelluna Immunotherapy AS, and Director at Zelluna ASA starting in 2025.
Former job includes Head-Immune Receptor Group at The Institute of Molecular Medicine from 1993 to 2000.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,45 % | 31/12/2025 | 132 478 ( 0,45 % ) | 251 688 $ | 30/06/2026 |
Postes actifs de Bent K. Jakobsen
| Sociétés | Poste | Début |
|---|---|---|
Zelluna Immunotherapy AS
 Zelluna Immunotherapy AS BiotechnologyHealth Technology Engages in development of off the shelf T-cell receptor natural killer cell therapies | Directeur/Membre du Conseil | - |
Engimmune Therapeutics AG
 Engimmune Therapeutics AG BiotechnologyHealth Technology Develops drugs to treat tumor cancers | Président | 01/05/2022 |
Accession Therapeutics Limited
 Accession Therapeutics Limited BiotechnologyHealth Technology Develops novel immuno-oncology therapeutics | Directeur Général | 01/06/2021 |
Anciens postes connus de Bent K. Jakobsen
| Sociétés | Poste | Fin |
|---|---|---|
The Institute of Molecular Medicine | Corporate Officer/Principal | 01/07/2000 |
| ADAPTIMMUNE THERAPEUTICS PLC | Fondateur | - |
Adaptimmune Ltd.
 Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Focuses on the use of T cell therapy to treat cancer and infectious diseases | Fondateur | - |
| IMMUNOCORE HOLDINGS PLC | Fondateur | - |
Avidex Ltd.
 Avidex Ltd. Pharmaceuticals: MajorHealth Technology Develops and discovers drugs for the treatment of cancer and autoimmune diseases | Fondateur | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
3
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Develops and discovers drugs for the treatment of cancer and autoimmune diseases | Health Technology |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Focuses on the use of T cell therapy to treat cancer and infectious diseases | Health Services |
The Institute of Molecular Medicine | |
Adaptimmune Therapeutics Plc
 Adaptimmune Therapeutics Plc BiotechnologyHealth Technology Manufactures vaccines and cancer immunotherapy products | Health Technology |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Engages in development of off the shelf T-cell receptor natural killer cell therapies | Health Technology |
Immunocore Holdings Plc
 Immunocore Holdings Plc BiotechnologyHealth Technology Operates as a biotechnology company which develops immunotherapies | Health Technology |
Engimmune Therapeutics AG
Engimmune Therapeutics AG BiotechnologyHealth Technology Develops drugs to treat tumor cancers | Health Technology |
Accession Therapeutics Limited
Accession Therapeutics Limited BiotechnologyHealth Technology Develops novel immuno-oncology therapeutics | Health Technology |
Choisissez Zonebourse 
